Boxun was promoted to Shanghai”specialized, special and new”
5月20日，在上海疫情防控关键时刻，Boxun was promoted to Shanghai”specialized, special and new”企业。早在2021年，上海博迅医疗生物仪器股份有限公司顺利通过层层审核，入选松江区2021年度“专精特新”中小企业名单。（Click to view）
The so-called specialization and novelty means specialization, refinement, characterization and novelty. Prior to this, it was highly valued to guide small and medium-sized enterprises to take the specialized, special and new development path. The fifth meeting of the central financial and Economic Commission stressed the need to give full play to the spirit of entrepreneurship and craftsmanship and cultivate a number of specialized, special and new small and medium-sized enterprises. From the policy level, specialization and innovation have become the most distinctive guidance for the high-quality development of small and medium-sized enterprises in China.
In accordance with the requirements of the notice of Shanghai Municipal Commission of economic and information technology on organizing the recommendation of”specialized, special and new” enterprises in 2021 (hjxq  No. 539), the Shanghai Municipal coordination office for promoting the development of small and medium-sized enterprises organized the recommendation and application of”specialized, special and new” small and medium-sized enterprises in Shanghai in 2021. After the enterprise application, recommendation by all districts, expert review and comprehensive evaluation, Recently, the list of”specialized, special and new” enterprises in Shanghai in 2021 was announced, and Shanghai Boxun medical biological Instrument Co., Ltd. was promoted to the municipal level”specialized, special and new” enterprise.
Founded in 1996, Shanghai Boxun medical biological Instrument Co., Ltd. is a national high-tech enterprise with a strong technology R & D team. It has its own characteristic theme projects in similar products. It has always maintained the progressiveness and its own characteristics of products in the same industry. It has achieved remarkable innovation results. It has successively obtained about 40 patents and software copyrights, and participated in the formulation of a number of national standards. Shanghai Boxun has realized the refinement of production, management and service in its operation and management, and created an efficient and high-quality brand. Shanghai Boxun has been focusing on its core business for a long time. With its strong technical strength, professional spirit of excellence and consistent quality, it has won unanimous praise from users.
In such a difficult period of epidemic prevention and control in Shanghai, this honor has added incomparable confidence to the company. In the future, Boxun will also continue to make efforts to carry forward the spirit of”broad and profound, fast and orderly”, give full play to its own technical advantages and experience accumulation, improve its core competitiveness and help the high-quality development of the industry.
Impact on the IPO of Beijing stock exchange
On June 9, Boxun medical (836504), the innovative layer company of the new third board, submitted the listing guidance filing materials of the Beijing stock exchange,The tutoring institution is Guojin securities。
6月9日，博迅医疗公告披露，公司提交北交所上市辅导备案材料，The tutoring institution is Guojin securities。
According to the announcement,On June 8, Boxun medical and Guojin securities signed the listing guidance agreement of Beijing stock exchange and submitted the guidance filing materials to Shanghai Securities Regulatory Bureau on the same day.
Boxun medical tips that the company is an innovative company that has been listed in the national small and medium-sized enterprise share transfer system for 12 months. According to the 2020 annual report (corrected) and the 2021 annual report disclosed by the company, the audited net profit attributable to the parent company in 2020 and 2021 (calculated based on the lower one before and after deducting the non recurring profit and loss) were RMB 1985.38 million and RMB 26.9867 million respectively, The weighted average return on net assets (calculated based on the lower one before and after deducting non recurring profits and losses) is 19.02%and 23.42%respectively. The net profits in the last two years are not less than 15million yuan and the weighted average return on net assets is not less than 8%on average, which meets the financial conditions for listing on the Beijing stock exchange as stipulated in article 2.1.3 of the listing rules.
Public information shows that,Boxun medical was listed on the new third board in may2016The company is mainly engaged in the R & D, production, sales and service of laboratory equipment and life science instruments. Its main products include microbial incubator series, pressure steam sterilizer series, purification equipment series, precision programmable oven series and other laboratory equipment and life science instruments, which are widely used in biopharmaceutical, health prevention and control, food safety, inspection and quarantine, environmental protection, agricultural scientific research and other fields.